Latest news with #ClaritevCorporation
Yahoo
3 days ago
- Business
- Yahoo
Claritev's (NYSE:CTEV) investors will be pleased with their splendid 109% return over the last year
Unfortunately, investing is risky - companies can and do go bankrupt. But when you pick a company that is really flourishing, you can make more than 100%. For example, the Claritev Corporation (NYSE:CTEV) share price had more than doubled in just one year - up 109%. It's also good to see the share price up 94% over the last quarter. On the other hand, longer term shareholders have had a tougher run, with the stock falling 82% in three years. Now it's worth having a look at the company's fundamentals too, because that will help us determine if the long term shareholder return has matched the performance of the underlying business. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Claritev isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one would hope for good top-line growth to make up for the lack of earnings. In the last year Claritev saw its revenue shrink by 3.3%. We're a little surprised to see the share price pop 109% in the last year. It just goes to show the market doesn't always pay attention to the reported numbers. Of course, it could be that the market expected this revenue drop. The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers). It's probably worth noting we've seen significant insider buying in the last quarter, which we consider a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. This free report showing analyst forecasts should help you form a view on Claritev We're pleased to report that Claritev shareholders have received a total shareholder return of 109% over one year. That certainly beats the loss of about 14% per year over the last half decade. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 3 warning signs for Claritev you should be aware of, and 1 of them makes us a bit uncomfortable. There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of undervalued small cap companies that insiders are buying. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
29-05-2025
- Business
- Yahoo
Claritev Upgraded to Overweight at Piper Sandler with a $44 Price Target
Piper Sandler has upgraded Claritev Corporation (NYSE:CTEV) shares, impressed by the company's first quarter 2025 results. On May 28, the firm upgraded the stock to an Overweight from a Neutral. Additionally, it hiked the price target to $44 from $19. The significant price hike underscores expectations of stronger performance. A closeup of a computer screen with data-driven analytics and business solutions displayed. The adjustment follows the technology data and insights company delivering a 1.4% year-over-year decrease in revenue to $231.3 million in Q1. Amid the total revenue decrease, the Claritev Payment and Revenue Integrity segment posted a 9.7% year-over-year growth. In addition, Claritev reaffirmed its full-year revenue guidance, indicating a potential bounce back to growth. Additionally, Piper Sandler upgraded Claritev, impressed by the signing of a three-year contract renewal with ELV. Establishing commercial partnerships backed by a growing project pipeline is expected to address customer concentration risks. Piper Sandler has echoed the strategic moves, reiterating they position Claritev to meet its 2025 guidance and continue growing in 2026. Claritev also achieved significant milestones in the quarter. It inked a deal with Burjeel Holdings to enhance its revenue cycle management in the Middle East and North Africa. The partnership will also streamline the reimbursement process and reduce unnecessary denials, enabling workforce efficiency in business operations. Claritev Corporation provides data analytics and cost management solutions for the U.S. healthcare industry. Using data-driven insights, it helps reduce medical costs by detecting claim overcharges, optimizing reimbursements, and managing provider networks. Its payment integrity services eliminate unnecessary charges and recover underpaid premiums, while its decision science tools improve benefit plans, clinical outcomes, and cost efficiency. Claritev serves insurance companies, health plans, TPAs, and other claim adjudication entities. While we acknowledge the potential of Claritev Corporation (NYSE:CTEV) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CTEV and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
29-05-2025
- Business
- Yahoo
Claritev Upgraded to Overweight at Piper Sandler with a $44 Price Target
Piper Sandler has upgraded Claritev Corporation (NYSE:CTEV) shares, impressed by the company's first quarter 2025 results. On May 28, the firm upgraded the stock to an Overweight from a Neutral. Additionally, it hiked the price target to $44 from $19. The significant price hike underscores expectations of stronger performance. A closeup of a computer screen with data-driven analytics and business solutions displayed. The adjustment follows the technology data and insights company delivering a 1.4% year-over-year decrease in revenue to $231.3 million in Q1. Amid the total revenue decrease, the Claritev Payment and Revenue Integrity segment posted a 9.7% year-over-year growth. In addition, Claritev reaffirmed its full-year revenue guidance, indicating a potential bounce back to growth. Additionally, Piper Sandler upgraded Claritev, impressed by the signing of a three-year contract renewal with ELV. Establishing commercial partnerships backed by a growing project pipeline is expected to address customer concentration risks. Piper Sandler has echoed the strategic moves, reiterating they position Claritev to meet its 2025 guidance and continue growing in 2026. Claritev also achieved significant milestones in the quarter. It inked a deal with Burjeel Holdings to enhance its revenue cycle management in the Middle East and North Africa. The partnership will also streamline the reimbursement process and reduce unnecessary denials, enabling workforce efficiency in business operations. Claritev Corporation provides data analytics and cost management solutions for the U.S. healthcare industry. Using data-driven insights, it helps reduce medical costs by detecting claim overcharges, optimizing reimbursements, and managing provider networks. Its payment integrity services eliminate unnecessary charges and recover underpaid premiums, while its decision science tools improve benefit plans, clinical outcomes, and cost efficiency. Claritev serves insurance companies, health plans, TPAs, and other claim adjudication entities. While we acknowledge the potential of Claritev Corporation (NYSE:CTEV) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CTEV and that has 100x upside potential, check out our report about the cheapest AI stock. READ NEXT: and. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
17-02-2025
- Business
- Associated Press
MultiPlan Enters New Era and Unveils New Brand, Claritev, Reflecting Company's Transformation and Mission to Support the Healthcare Continuum
Claritev Corporation ('Claritev' or the 'Company') (NYSE: MPLN), formerly known as MultiPlan, a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today a corporate rebrand to Claritev. The Company will also start trading with a new ticker, CTEV, on the New York Stock Exchange on February 28, 2025. Founded in 1980, the Company plays a significant role in delivering access to care through provider networks, identifying healthcare cost savings, lowering out-of-pocket costs and reducing or eliminating balance bills for patients across the U.S. The rebrand to Claritev reflects our increased investment, transformation and commitment to bringing transparency to a broader set of the healthcare ecosystem with increased innovation, products and partners. 'Claritev is proud of the clients that we serve and has come a long way since our founding while playing an important role in the healthcare industry. We will continue to do that,' said Travis Dalton, Chairman, CEO and President of Claritev. 'However, today's announcement opens a new chapter for Claritev as we accelerate the use of innovation and technology to better serve our core clients and the broader healthcare ecosystem. By embracing technology modernization, data infrastructure, cutting edge tools like AI and scale partners, we believe we will be best positioned against the competition, but most importantly, best equipped to bring value to our clients and those they serve. Healthcare will continue to evolve and we must evolve with it. This will allow us to deepen our line of products that deliver transparent and fair data insights and make healthcare more affordable for all.' The Company was initially founded as a New York-based hospital network. Since then, the Company has grown into a national organization, delivering sophisticated technology, data analytics and innovative solutions to more than 700 healthcare payors, 100,000 employers, 60 million consumers and 1.4 million contracted providers. Partners, providers, payors and consumers will start to see the new brand come to life following today's announcement and our brand launch at ViVE 2025. The rebrand will have no impact on the Company's existing suite of offerings. About Claritev MultiPlan is now Claritev, a healthcare technology, data and insights company focused on delivering affordability, transparency and quality to the U.S. healthcare system. Led by a team of deeply experienced associates, data scientists, and innovators Claritev provides cutting-edge solutions and services fueled by over 40 years of claims processing data. Claritev leverages world-class technology and AI to power a robust enterprise platform that delivers meaningful insights to drive affordability and price transparency, and optimizes networks and benefits design in healthcare. By developing purpose-built solutions that support all key stakeholders — including payors, employers, patients, providers and third parties — Claritev is dedicated to making healthcare more accessible and affordable for all. AVP, Marketing & Communication Claritev 781-895-3118 [email protected] Investor Relations Jason Wong SVP, Treasury & Investor Relations Claritev 866-909-7427 [email protected] Shawna Gasik AVP, Investor Relations Claritev SOURCE: Claritev Corporation Copyright Business Wire 2025. PUB: 02/17/2025 06:04 AM/DISC: 02/17/2025 06:04 AM
